Intelligence Profile
Clinical Applications
TB-500 is a synthetic peptide based on an active fragment (amino acids 17-23) of thymosin β₄, a naturally occurring protein involved in cellular repair and regeneration processes. Current clinical evidence for TB-500 remains extremely limited.
Musculoskeletal and Athletic Applications
TB-500 is commonly promoted for musculoskeletal injuries and athletic performance enhancement, though rigorous clinical evidence supporting these uses is lacking. A 2026 systematic review on peptide therapies for musculoskeletal conditions and athletic performance included TB-500 among therapies examined for safety and efficacy, but specific findings for TB-500 were not detailed in the available evidence.
Cardiovascular Research
The only identified clinical trial investigating TB-500 is currently recruiting participants to evaluate its effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). This Phase I/II study aims to assess TB-500's impact on cardiovascular markers, but results are not yet available.
Regulatory and Safety Considerations
TB-500 has been identified as a substance with "doping potential" and is monitored in anti-doping programs, particularly in equine sports. The development of analytical methods to detect TB-500 in biological samples reflects concerns about its use as a performance-enhancing substance rather than established therapeutic benefits.
Evidence Limitations
The clinical evidence base for TB-500 is notably sparse. While the compound is marketed and used for various conditions, particularly musculoskeletal injuries and recovery enhancement, peer-reviewed clinical trial data demonstrating safety and efficacy are extremely limited. Most available research focuses on detection methods rather than therapeutic outcomes.
Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional before considering any peptide therapy, especially given the limited clinical evidence and regulatory status of TB-500.